The depressed economy has hit all medtech stocks, but some harder than others, in particular, those that rely on nervous consumers to pay out of pocket for elective procedures, namely, medical aesthetics, and refractive surgery. J&J was thus able to acquired breast-implant manufacturer Mentor for much less than it would have had to pay a year ago, when it was first rumored to be looking to get into the aesthetics market.
An old saw suggests dog food and funeral services are recession-proof, but now it’s clear from recent stock prices that aesthetic procedures are not.
No segment within the medical device industry is better positioned to capitalize on the positive feelings that come with good...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
